Evaluation of albutoin as an antiepileptic drug

James Cereghino, Joseph T. Brock, John C. Van Meter, J. Kiffin Penry, Lawrence D. Smith, Pearl Fisher, Jonas Ellenberg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A double-blind, controlled study of efficacy and bioavailability of the investigational antiepileptic drug albutoin was performed in a population of institutionalized patients whose seizures were not completely controlled by therapeutic dosages, as determined by serum levels, of combinations of currently available antiepileptic drugs. Albutoin did not appear to be as effective as diphenylhydantoin, primidone, or phenobarbital in controlling seizure frequency. Serum albutoin levels indicated the drug was poorly absorbed at dosages up to 1,200 mg per day. Nausea, anorexia, and weight loss were significant problems in over 10% of the patients receiving 1,200 mg of albutoin per day. Few controlled studies are available as models for evaluating the efficacy of antiepileptic drugs. With minor modifications, the double-blind study design described could be used as a means o f rapidly (21 days) evaluating drugs as antiepileptic agents.

Original languageEnglish (US)
Pages (from-to)406-416
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume15
Issue number4
StatePublished - Apr 1974
Externally publishedYes

Fingerprint

Anticonvulsants
Double-Blind Method
Seizures
Primidone
Investigational Drugs
Phenytoin
Anorexia
Phenobarbital
Serum
Pharmaceutical Preparations
Nausea
Biological Availability
Weight Loss
albutoin
Population
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cereghino, J., Brock, J. T., Van Meter, J. C., Kiffin Penry, J., Smith, L. D., Fisher, P., & Ellenberg, J. (1974). Evaluation of albutoin as an antiepileptic drug. Clinical Pharmacology and Therapeutics, 15(4), 406-416.

Evaluation of albutoin as an antiepileptic drug. / Cereghino, James; Brock, Joseph T.; Van Meter, John C.; Kiffin Penry, J.; Smith, Lawrence D.; Fisher, Pearl; Ellenberg, Jonas.

In: Clinical Pharmacology and Therapeutics, Vol. 15, No. 4, 04.1974, p. 406-416.

Research output: Contribution to journalArticle

Cereghino, J, Brock, JT, Van Meter, JC, Kiffin Penry, J, Smith, LD, Fisher, P & Ellenberg, J 1974, 'Evaluation of albutoin as an antiepileptic drug', Clinical Pharmacology and Therapeutics, vol. 15, no. 4, pp. 406-416.
Cereghino J, Brock JT, Van Meter JC, Kiffin Penry J, Smith LD, Fisher P et al. Evaluation of albutoin as an antiepileptic drug. Clinical Pharmacology and Therapeutics. 1974 Apr;15(4):406-416.
Cereghino, James ; Brock, Joseph T. ; Van Meter, John C. ; Kiffin Penry, J. ; Smith, Lawrence D. ; Fisher, Pearl ; Ellenberg, Jonas. / Evaluation of albutoin as an antiepileptic drug. In: Clinical Pharmacology and Therapeutics. 1974 ; Vol. 15, No. 4. pp. 406-416.
@article{9e73325c846648779439d37450e9f566,
title = "Evaluation of albutoin as an antiepileptic drug",
abstract = "A double-blind, controlled study of efficacy and bioavailability of the investigational antiepileptic drug albutoin was performed in a population of institutionalized patients whose seizures were not completely controlled by therapeutic dosages, as determined by serum levels, of combinations of currently available antiepileptic drugs. Albutoin did not appear to be as effective as diphenylhydantoin, primidone, or phenobarbital in controlling seizure frequency. Serum albutoin levels indicated the drug was poorly absorbed at dosages up to 1,200 mg per day. Nausea, anorexia, and weight loss were significant problems in over 10{\%} of the patients receiving 1,200 mg of albutoin per day. Few controlled studies are available as models for evaluating the efficacy of antiepileptic drugs. With minor modifications, the double-blind study design described could be used as a means o f rapidly (21 days) evaluating drugs as antiepileptic agents.",
author = "James Cereghino and Brock, {Joseph T.} and {Van Meter}, {John C.} and {Kiffin Penry}, J. and Smith, {Lawrence D.} and Pearl Fisher and Jonas Ellenberg",
year = "1974",
month = "4",
language = "English (US)",
volume = "15",
pages = "406--416",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Evaluation of albutoin as an antiepileptic drug

AU - Cereghino, James

AU - Brock, Joseph T.

AU - Van Meter, John C.

AU - Kiffin Penry, J.

AU - Smith, Lawrence D.

AU - Fisher, Pearl

AU - Ellenberg, Jonas

PY - 1974/4

Y1 - 1974/4

N2 - A double-blind, controlled study of efficacy and bioavailability of the investigational antiepileptic drug albutoin was performed in a population of institutionalized patients whose seizures were not completely controlled by therapeutic dosages, as determined by serum levels, of combinations of currently available antiepileptic drugs. Albutoin did not appear to be as effective as diphenylhydantoin, primidone, or phenobarbital in controlling seizure frequency. Serum albutoin levels indicated the drug was poorly absorbed at dosages up to 1,200 mg per day. Nausea, anorexia, and weight loss were significant problems in over 10% of the patients receiving 1,200 mg of albutoin per day. Few controlled studies are available as models for evaluating the efficacy of antiepileptic drugs. With minor modifications, the double-blind study design described could be used as a means o f rapidly (21 days) evaluating drugs as antiepileptic agents.

AB - A double-blind, controlled study of efficacy and bioavailability of the investigational antiepileptic drug albutoin was performed in a population of institutionalized patients whose seizures were not completely controlled by therapeutic dosages, as determined by serum levels, of combinations of currently available antiepileptic drugs. Albutoin did not appear to be as effective as diphenylhydantoin, primidone, or phenobarbital in controlling seizure frequency. Serum albutoin levels indicated the drug was poorly absorbed at dosages up to 1,200 mg per day. Nausea, anorexia, and weight loss were significant problems in over 10% of the patients receiving 1,200 mg of albutoin per day. Few controlled studies are available as models for evaluating the efficacy of antiepileptic drugs. With minor modifications, the double-blind study design described could be used as a means o f rapidly (21 days) evaluating drugs as antiepileptic agents.

UR - http://www.scopus.com/inward/record.url?scp=0016138563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016138563&partnerID=8YFLogxK

M3 - Article

C2 - 4206927

AN - SCOPUS:0016138563

VL - 15

SP - 406

EP - 416

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -